Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, Alexander Vasilyev et al.|Annals of Oncology|2022Cited by 144
Activation of Wnt Signaling Pathway by Human Papillomavirus E6 and E7 Oncogenes in HPV16-Positive Oropharyngeal Squamous Carcinoma CellsTheodore Rampias, Amanda Psyrri|Molecular Cancer Research|2010Cited by 120
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Epaminontas Samantas et al.|ESMO Open|2021Cited by 93
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinomaNiki Gavrielatou, Amanda Psyrri|Annals of Oncology|2023Cited by 50